Pharmaceutical News

RSS

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Study observes that long-term use of antihypertensive drugs associated with breast cancer risk

Older women who take certain types of medication to combat high blood pressure may be putting themselves at greater risk for developing breast cancer, according to a new study by a team of Fred Hutchinson Cancer Research Center scientists led by Christopher Li, M.D., Ph.D.

6 Aug 2013

Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine, a JAMA Network publication.

6 Aug 2013

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.

6 Aug 2013

Novel way to dramatically raise potency of drug candidates targeting RNA

Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly increasing their potential as therapeutic agents.

6 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

New systematic review finds no evidence that antioxidants boost women's fertility

There is no high quality evidence that antioxidant supplements help to increase a woman's chances of having a baby, according to the results of a new systematic review. The review, published in The Cochrane Library, found women were no more likely to conceive when taking oral antioxidants and that there was limited information about potential harms.

5 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Research Fellow published book on how public environments are affected by injecting drug use

Dr Stephen Parkin, a Research Fellow in Human and Health Sciences at the University of Huddersfield, has published a book focusing on how public environments are affected by injecting drug use.

3 Aug 2013

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

Prothrombin complex concentrates are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly used therapy.

3 Aug 2013

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.

3 Aug 2013

IQWiG dossier assessment finds no added benefit of lixisenatide

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.

3 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

China CDC, Aeras sign MOU to advance research, development of new TB vaccines

With the global tuberculosis epidemic becoming more deadly, costly, and difficult to treat, Chinese Center for Disease Control and Prevention and Aeras today signed a memorandum of understanding to advance research and development of new tuberculosis vaccines. An improved TB vaccine offers the best hope for eliminating this airborne infectious disease that kills 1.4 million people worldwide each year.

3 Aug 2013

New findings could enable development of effective drugs for addiction with fewer side effects

Scientists from the Florida campus of The Scripps Research Institute have described findings that could enable the development of more effective drugs for addiction with fewer side effects.

3 Aug 2013

Physicians prescribe strongest antibiotics capable of killing multiple kinds of bacteria

When U.S. physicians prescribe antibiotics, more than 60 percent of the time they choose some of the strongest types of antibiotics, referred to as "broad spectrum," which are capable of killing multiple kinds of bacteria, University of Utah researchers show in a new study.

2 Aug 2013

ICSD, SAGE launch journal that provides information on drugs to public and professionals

SAGE and the Independent Scientific Committee on Drugs (ICSD) today announced the launch of Drug Science, Policy and Law, an online journal supporting the ICSD's goals of providing accessible information on drugs to the public and professionals.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.

2 Aug 2013

Health care providers are missing opportunities to improve teens' vaccination coverage

Health care providers are missing opportunities to improve teens' vaccination coverage, reports a new study in the Journal of Adolescent Health.

2 Aug 2013

Pharmaceutical News

Ensemble Therapeutics initiates research and development collaboration with Novartis

Study observes that long-term use of antihypertensive drugs associated with breast cancer risk

Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Novel way to dramatically raise potency of drug candidates targeting RNA

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

New systematic review finds no evidence that antioxidants boost women's fertility

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Research Fellow published book on how public environments are affected by injecting drug use

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

IQWiG dossier assessment finds no added benefit of lixisenatide

Added benefit of thyroid cancer drug vandetanib not proven

China CDC, Aeras sign MOU to advance research, development of new TB vaccines

New findings could enable development of effective drugs for addiction with fewer side effects

Physicians prescribe strongest antibiotics capable of killing multiple kinds of bacteria

ICSD, SAGE launch journal that provides information on drugs to public and professionals

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Health care providers are missing opportunities to improve teens' vaccination coverage

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News